EDI200

DRUG3 trials

Sponsors

Edimer Pharmaceuticals

Conditions

X-Linked Hypohidrotic Ectodermal DysplasiaX-linked Hypohidrotic Ectodermal Dysplasia

Phase 1

A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200

CompletedNCT01564225

Edimer PharmaceuticalsX-linked Hypohidrotic Ectodermal Dysplasia

Start: 2012-05-31End: 2013-04-30Updated: 2013-11-27

Phase 2

Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

CompletedNCT01775462

Edimer PharmaceuticalsX-Linked Hypohidrotic Ectodermal Dysplasia

Start: 2013-04-30End: 2015-12-31Target: 6Updated: 2016-01-20

Unknown Phase

Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002

Edimer PharmaceuticalsX-linked Hypohidrotic Ectodermal Dysplasia

Start: 2014-03-31End: 2025-03-31Updated: 2017-09-05